user

Savolitinib (savo) plus osimertinib (osi) vs savo plus placebo (PBO) in patients (pts) with EGFR-mutated (EGFRm), MET-amplified advanced NSCLC with progression on osi

被引：0
|
作者：
Yang, James Chih-Hsin
Chen, Yuh-Min
Batra, Ullas
Do, Kien
Sitthideatphaiboon, Piyada
Danchaivijitr, Pongwut
Lee, Kang-Yun
Chindaprasirt, Jarin
Yang, Cheng-Ta
Chang, Gee-Chen
Charoentum, Chaiyut
Ungtrakul, Teerapat
Moran, Juan Ignacio Hernandez
Hartmaier, Ryan
Haskins, Matthew
Xu, Wanning
Riess, Jonathan W.
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-CT251
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT251
引用
收藏
页数：3
相关论文
共 46 条
  • [1] The effect of savolitinib plus osimertinib on ctDNA clearance in patients with EGFR mutation positive (EGFRm) MET-amplified NSCLC in the TATTON study
    Hartmaier, Ryan
    Han, Ji-Youn
    Ahn, Myung-Ju
    Cho, Byoung Chul
    Cantarini, Mireille
    Frewer, Paul
    Frigault, Melanie M.
    Oxnard, Geoffrey
    [J]. CANCER RESEARCH, 2020, 80 (16)
  • [2] Osimertinib plus Savolitinib in pts with EGFRm MET-Amplified/Overexpressed NSCLC: Phase Ib TATTON Parts B and D Final Analysis
    Han, J.
    Sequist, L.
    Ahn, M.
    Cho, B. C.
    Yu, H.
    Kim, S.
    Yang, J. C.
    Lee, J. S.
    Su, W.
    Kowalski, D. M.
    Orlov, S.
    Cantarini, M.
    Ren, S.
    Frewer, P.
    Ou, X.
    Janne, P.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S227 - S228
  • [3] TATTON Ph Ib Expansion Cohort: Osimertinib plus Savolitinib for Pts with EGFR-Mutant MET-Amplified NSCLC after Progression on Prior EGFR-TKI
    Ahn, M.
    Han, J.
    Sequist, L.
    Cho, B. C.
    Lee, J. S.
    Kim, S.
    Su, W.
    Tsai, C.
    Yang, J. C.
    Yu, H.
    Horn, L.
    Lee, K.
    Haddad, V.
    Frigault, M.
    Ahmed, G.
    Yang, L.
    Ghiorghiu, D.
    Oxnard, G.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1768 - S1768
  • [4] Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by MET-D1228 and MET-Y1230 Mutations in EGFR-Mutated MET-Amplified Lung Cancer
    Piper-Vallillo, Andrew J.
    Halbert, Brian T.
    Rangachari, Deepa
    Kobayashi, Susumu S.
    Costa, Daniel B.
    [J]. JTO CLINICAL AND RESEARCH REPORTS, 2020, 1 (04):
  • [5] A Phase Ib Trial of Savolitinib plus Gefitinib for Chinese Patients with EGFR-Mutant MET-Amplified Advanced NSCLC
    Yang, J. -
    Fang, J.
    Shu, Y.
    Chang, J.
    Chen, G.
    He, J.
    Li, W.
    Liu, X.
    Yang, N.
    Zhou, C.
    Huang, J.
    Yang, L.
    Handzel, A.
    Frigault, M.
    Ahmed, G.
    Egile, C.
    Morgan, S.
    Wu, Y.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1769 - S1769
  • [6] Treatment adherence and clinical outcomes of osimertinib (Osi) among ethnic-minority patients (pts) with EGFR-mutated NSCLC
    Lee, Matthew
    Miao, Emily
    Zhang, Chenxin
    Xue, Xiaonan
    Tuckman, Steven
    Halmos, Balazs
    Cheng, Haiying
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] Osimertinib (OSI) vs Standard of Care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA
    Bischoff, H. G.
    Rueckert, A.
    Reinmuth, N.
    Grohe, C.
    Bohnet, S.
    zum Bueschenfelde, C. M.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 187 - 187
  • [8] A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer
    Jin-Ji Yang
    Jian Fang
    Yong-Qian Shu
    Jian-Hua Chang
    Gong-Yan Chen
    Jian Xing He
    Wei Li
    Xiao-Qing Liu
    Nong Yang
    Caicun Zhou
    Jian An Huang
    Melanie M. Frigault
    Ryan Hartmaier
    Ghada F. Ahmed
    Coumaran Egile
    Shethah Morgan
    Remy B. Verheijen
    Anders Mellemgaard
    Liu Yang
    Yi-Long Wu
    [J]. Investigational New Drugs, 2021, 39 : 477 - 487
  • [9] SAVANNAH: A Phase II trial of osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET driven (MET plus ), locally advanced or metastatic non small cell lung cancer (NSCLC), following disease progression on osimertinib.
    Oxnard, Geoffrey R.
    Cantarini, Mireille
    Frewer, Paul
    Hawkins, George
    Peters, Jane
    Howarth, Paul
    Ahmed, Ghada F.
    Sahota, Tarjinder
    Hartmaier, Ryan
    Li-Sucholeiki, Xiaocheng
    Ahn, Myung-Ju
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [10] Phase 1/1b study of telisotuzumab vedotin (Teliso-V) plus osimertinib (Osi), after failure on prior Osi, in patients with advanced, c-Met overexpressing, EGFR-mutated non-small cell lung cancer (NSCLC).
    Goldman, Jonathan W.
    Horinouchi, Hidehito
    Cho, Byoung Chul
    Tomasini, Pascale
    Dunbar, Martin
    Hoffman, David
    Parikh, Apurvasena
    Blot, Vincent
    Camidge, D. Ross
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345